Recombinant Mouse T-cell surface glycoprotein YE1/48 (Klra1)

What is Recombinant Mouse T-cell surface glycoprotein YE1/48 (KLRA1)?

Recombinant Mouse T-cell surface glycoprotein YE1/48 (KLRA1) is a receptor protein found on natural killer (NK) cells that recognizes H-2d alleles and functions as an inhibitory receptor. This protein inhibits the activity of NK cells, thereby preventing cell lysis of target cells . Originally identified through monoclonal antibodies YE1/48 and YE1/32, it was characterized as a disulfide-linked dimeric antigen consisting of two 45,000-50,000 Mr subunits . Though initially thought to resemble the T-cell receptor alpha/beta due to similar molecular weight and structure, subsequent research confirmed it as a distinct novel T-cell surface molecule .

What is the molecular structure and composition of YE1/48 (KLRA1)?

YE1/48 is a Type II membrane protein comprising 262 amino acids with a molecular weight of approximately 30,500 Da before glycosylation . The protein's structural organization includes:

• 44 amino acids in the N-terminal cytoplasmic domain

• 22 amino acids in the transmembrane domain

• 196 amino acids in the C-terminal extracellular domain

The protein contains three potential N-linked glycosylation sites in the extracellular domain, all of which are likely utilized in the mature protein, contributing to its final higher molecular weight . After enzymatic deglycosylation with Endoglycosidase F, the peptide cores were revealed to be approximately 32-38 kDa under reducing conditions, confirming at least three glycosylation side-chains .

The extracellular domain notably contains an arginine-glycine-aspartic acid tripeptide, which represents a potential cell-adhesive binding site, and a sequence resembling the consensus domain of metal-binding proteins, though the functionality of these features remains undetermined .

How is YE1/48 expression regulated in different cell types?

YE1/48 exhibits a distinctive expression pattern across different cell populations. The protein is expressed at high levels on some T lymphoma cell lines but shows very low expression on normal lymphocytes . Gene expression analysis indicates that the YE1/48 gene is expressed at minimal levels across a wide range of lymphoid cells with no restriction to particular differentiation stages .

Interestingly, YE1/48 expression appears to be induced in pre-B cells following transformation by Abelson virus, suggesting a potential association between YE1/48 expression and the transformation process in both T and pre-B cells . This pattern indicates possible involvement in cellular transformation pathways and makes it an intriguing target for cancer immunology research.

What methods are optimal for studying YE1/48 (KLRA1) protein interactions?

For investigating YE1/48 protein interactions, researchers should employ a multi-faceted approach combining:

• Immunoprecipitation: Using specific monoclonal antibodies such as YE1/48 and YE1/32 to isolate the protein and its binding partners. Sequential immunoprecipitation techniques have been effectively used to distinguish YE1/48 from T-cell receptor complexes .

• Functional ELISA assays: Recombinant YE1/48 binding capability can be assessed through functional ELISA to determine biological activity .

• SDS-PAGE analysis: Both reducing and non-reducing conditions should be employed for comprehensive analysis. Diagonal gel analysis (non-reducing versus reducing SDS-PAGE) has proven valuable for comparing YE1/48 with other T-cell surface proteins .

• Affinity chromatography: This technique has been successfully used for purification of YE1/48 antigen from cell lines with high expression, such as MBL-2(4.1) cells .

• Western blotting: For detection and quantification of YE1/48, with detection enhanced by using recombinant protein (>90% purity as determined by SDS-PAGE) as a standard .

How can enzymatic modification of YE1/48 affect T-cell signaling?

Enzymatic modifications of cell surface glycoproteins like YE1/48 can significantly enhance T-cell functionality. Research demonstrates two primary enzymatic approaches:

• Sialidase treatment: Using Clostridium perfringens-derived sialidase (CP-Siase) to cleave terminal sialic acids linked via α(2,3), α(2,6) or α(2,8) binding to N- or O-glycosidic-bound oligosaccharide chains . This treatment enhances:

  • Anti-CD3-mediated Ca²⁺ response

  • Activation-induced CD69 and CD25 expression

  • Production of interleukin-2 and interferon-γ

  • Granzyme B expression and cytolytic activity

• O-linked glycoprotein endopeptidase (OSGE) treatment: This neutral metalloprotease cleaves the protein backbone of O-glycosylated proteins on serine and threonine residues, affecting targets like CD34, CD43, CD44, and CD45 . Similar to sialidase treatment, OSGE enhances T-cell functionality across multiple parameters.

These enzymatic modifications have demonstrated particular efficacy in restoring function in aged T cells, suggesting potential therapeutic applications in age-related immune decline .

What expression systems yield functional recombinant YE1/48?

For producing functional recombinant YE1/48, the E. coli expression system has been effectively employed to produce the 1-262 amino acid fragment with either a His-tag or in tag-free form . The recombinant protein from this system demonstrates proper folding and retains biological activity as determined by binding ability in functional ELISA assays .

The resulting recombinant protein exhibits >90% purity when analyzed by SDS-PAGE and can be used in multiple applications including ELISA, Western blotting, and immunoprecipitation . This expression system provides a reliable source of functional protein for research applications without the complexity of mammalian expression systems, though the bacterial expression means post-translational modifications like glycosylation will differ from native protein.

How does YE1/48 (KLRA1) compare to human NK cell receptors?

YE1/48 (KLRA1) functions as an inhibitory receptor on murine NK cells that recognizes specific MHC class I molecules (H-2d alleles), preventing NK cell-mediated cytolysis . While initial sequence comparisons showed no significant homology with other known protein sequences in early databases , the protein is now recognized as part of the killer cell lectin-like receptor family.

The presence of an arginine-glycine-aspartic acid tripeptide in the extracellular domain of YE1/48 suggests potential cell adhesion functionality that might be analogous to certain human NK cell receptors, though confirmation of this function remains pending .

What role might YE1/48 play in cancer immunology research?

YE1/48's significantly elevated expression in T lymphoma lines compared to normal lymphocytes makes it a potential marker for malignant transformation . Furthermore, its induction in pre-B cells following Abelson virus transformation suggests a broader association with lymphoid cell transformation . These characteristics position YE1/48 as a valuable target for cancer immunology research in several ways:

• Tumor marker: The differential expression between normal and transformed cells makes YE1/48 a potential biomarker for detecting malignant transformation in lymphoid cells.

• Immune evasion mechanism: As an inhibitory receptor on NK cells, overexpression of YE1/48 or its ligands could potentially contribute to immune evasion by cancer cells by preventing NK cell-mediated cytolysis.

• Therapeutic target: Modifying YE1/48 activity through enzymatic treatment or targeted antibodies could potentially enhance anti-tumor immune responses. The enhancement of CD8 T-cell function observed after enzymatic modification of surface glycoproteins suggests similar approaches might improve tumor immunosurveillance.

How do age-related changes in glycosylation affect YE1/48 function?

Age-related alterations in T-cell surface glycosylation patterns may significantly impact YE1/48 function and contribute to immunosenescence. Research has demonstrated that:

• T-cell development and differentiation are accompanied by changes in cell surface N- and O-linked glycans and alterations in glycoprotein sialylation .

• These changes can regulate T-cell responses through direct effects on the intrinsic properties of specific proteins or by modulating the binding of cell surface proteins to specific carbohydrate moieties .

• Terminal sialic acid residues on T-cell surfaces predominantly bind to galactose through α(2,3) and less frequently through α(2,6) links, with the α(2,3) bond being particularly important in CD8 T-cell homeostasis and CD8-MHC class I interactions .

• Enzymatic treatments that modify glycosylation (using either CP-Siase or OSGE) can enhance multiple aspects of T-cell function in both young and aged mice, suggesting that glycosylated surface proteins may hinder optimal T-cell activation and function regardless of age .

This research opens the possibility of significantly improving T-cell function in older individuals through enzymatic alteration of surface glycoproteins like YE1/48, potentially counteracting aspects of age-related immune decline .

What are common challenges in detecting native YE1/48 expression?

Detection of native YE1/48 presents several challenges for researchers:

• Low expression levels: YE1/48 is expressed at very low levels in normal lymphocytes, making detection in primary cells difficult without sensitive techniques .

• Cross-reactivity concerns: Early characterization revealed similarities in molecular weight and structure with the T-cell receptor, leading to potential misidentification . Researchers should employ sequential immunoprecipitation or other specific techniques to distinguish between these molecules.

• Strain-specific variations: Restriction fragment length polymorphism has been demonstrated across different mouse strains (C57BL/6, BALB/c, and C3H) , suggesting potential variations in expression or structure that could affect detection depending on the strain being studied.

To overcome these challenges, researchers should consider:

• Using highly sensitive flow cytometry with fluorescently labeled monoclonal antibodies

• Employing cell enrichment techniques before analysis

• Including proper controls specific to the mouse strain being studied

• Utilizing recombinant YE1/48 as a positive control for assay validation

How can functionality of recombinant YE1/48 be verified?

Verifying the functionality of recombinant YE1/48 is crucial for research applications. The following methodological approaches are recommended:

• Functional ELISA: This is the primary method for determining biological activity through binding assays . Researchers should establish standard curves using validated recombinant protein preparations.

• Binding studies with natural ligands: Verify interaction with H-2d alleles or other identified ligands using surface plasmon resonance or similar technologies.

• Inhibition assays: Functional recombinant YE1/48 should inhibit NK cell activity in controlled assays, which can be measured through cytotoxicity or degranulation assays.

• Structural verification: Confirm proper disulfide linkage through non-reducing versus reducing SDS-PAGE comparison, as native YE1/48 exists as a disulfide-linked dimer .

• Glycosylation analysis: While E. coli-expressed recombinant protein will lack mammalian glycosylation, researchers working with mammalian expression systems should verify glycosylation status at the three potential N-linked sites using glycosidase digestion and mass spectrometry.

What are promising areas for future YE1/48 research?

Several promising research directions for YE1/48 (KLRA1) warrant further investigation:

• Therapeutic applications of enzymatic modification: Building on findings that enzymatic modification of T-cell surface glycoproteins enhances function , research could explore whether similar approaches targeting YE1/48 might improve NK cell function in immunocompromised states or aging.

• Role in cancer immunosurveillance: Given YE1/48's differential expression between normal and malignant cells , and its function as an NK cell inhibitory receptor , further investigation into its role in tumor immune evasion could yield valuable insights for cancer immunotherapy.

• Structural biology approaches: Determining the crystal structure of YE1/48 would facilitate deeper understanding of its binding properties and potentially enable structure-based drug design for immunomodulatory applications.

• Transgenic and knockout models: Development of YE1/48 transgenic or knockout mouse models would allow for more detailed investigation of its physiological functions in vivo and potential roles in disease states.

• Investigation of homologous genes: Genomic analysis has suggested the existence of other genes highly homologous to YE1/48 , warranting exploration of this potential gene family and its collective functions in immune regulation.

How might single-cell analysis techniques advance YE1/48 research?

Single-cell analysis technologies offer significant opportunities to advance understanding of YE1/48 biology:

• Single-cell transcriptomics: Would enable detailed characterization of YE1/48 expression across heterogeneous lymphocyte populations, potentially revealing previously unrecognized expression patterns in rare subpopulations.

• CyTOF and spectral flow cytometry: These advanced flow cytometry techniques allow simultaneous detection of numerous surface markers, enabling comprehensive phenotyping of YE1/48-expressing cells and correlation with functional states.

• Single-cell proteomics: Could reveal cell-to-cell variations in YE1/48 protein levels, post-translational modifications, and interacting partners not detectable in bulk analysis.

• Spatial transcriptomics: Would provide insights into the tissue-specific expression of YE1/48 and its relationship to cellular microenvironments, particularly in lymphoid tissues and tumor interfaces.

These single-cell approaches could overcome the limitations of bulk analysis methods, particularly important for YE1/48 research given its differential expression between normal and transformed cells and generally low expression levels in normal lymphocytes .